Back to first-pass browser

First-pass extracted concept

CRISPR-Cas delivery platforms

Candidate: concept label1 source documents5 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This source frames delivery platforms as the enabling layer for transporting CRISPR-Cas cargo into cells and tissues. The abstract groups these platforms into viral, physical, and nanoparticle-based strategies.

Source 1DOIPubMed

Resources required

The delivery problem involves Cas protein or base/prime editor fusions, guide RNA, and sometimes DNA repair templates. Packaging, stability, and cellular uptake are explicit constraints.

Source 1DOIPubMed

What problem it solves

It addresses the challenge of delivering large, chemically distinct genome-editing components to the right cells and tissues.

Source 1DOIPubMed

What it does not solve

The abstract does not establish one specific platform as universally solving tissue specificity, intracellular variability, editing efficiency, or off-target risk.

Source 1DOIPubMed

Alternatives

The abstract contrasts viral vectors, non-viral physical approaches, and nanoparticle-based modalities as alternative delivery strategy classes.

Source 1DOIPubMed

Evidence Snippets

This review outlines the key challenges in the delivery of CRISPR technologies as well provides a comprehensive overview of both current and emerging delivery strategies
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1application scopesupports2026Source 1DOIPubMed

CRISPR-Cas9 applications discussed in the review include gene therapy, immune cell engineering for cancer therapies, and agricultural innovation.

Claim 2capabilitysupports2026Source 1DOIPubMed

CRISPR-Cas systems transformed genome editing through high precision, and base editors and prime editors further enhance specificity by enabling targeted nucleotide changes without double-strand DNA breaks.

Claim 3challengesupports2026Source 1DOIPubMed

CRISPR delivery is further limited by tissue and cell-type specificity, differential intracellular environments, variable editing efficiencies, and persistent off-target genome modification risk.

Claim 4challengesupports2026Source 1DOIPubMed

Targeted delivery remains a major challenge for CRISPR technologies because their components are large and chemically distinct, complicating packaging, stability, and cellular uptake.

Claim 5scopesupports2026Source 1DOIPubMed

Current and emerging CRISPR delivery strategies include viral vectors, non-viral physical approaches, and nanoparticle-based modalities.